Perth-based company PYC Therapeutics will take early human data on its polycystic kidney disease drug to the American Society of Nephrology conference in Denver on 22 October.

PYC Therapeutics shares fell nearly 8% amid heightened volatility, with investors focused on upcoming safety and efficacy data for its experimental treatment for inherited kidney disease.

JERSEY CITY - SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, announced completion of a Phase 1 study of SCY-770, a ...

"Rocky" franchise star Dolph Lundgren was considering ending his life after a yearslong battle with kidney cancer. A second opinion "saved" him.

Panelists discuss how recent data from the KEYNOTE-564 trial has changed their approaches to treating patients with renal cell carcinoma by implementing adjuvant pembrolizumab therapy for high-risk ...

PYC Therapeutics shares gained 5.1% as investors looked ahead to clinical data for PYC-003, an experimental RNA treatment for inherited polycystic kidney disease.

The prevalence of kidney stones has doubled in the past 30 years. Academic researchers are searching for better solutions for ...

SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously ...

SCYNEXIS, Inc. announced completion of a Phase 1 study of SCY-770, a first-in-class, selective and direct AMP-activated protein kinase (AMPK) activator. The study was conducted to evaluate the safety ...

Every year in the United States alone, over 100,000 women are diagnosed with gynecological cancer, and often, by the time a woman is diagnosed, the disease has progressed to a far more serious or even ...

Holmium:YAG and thulium fiber lasers demonstrate similar effectiveness for dusting kidney stones, with similar stone-free rates, procedure durations, and quality-of-life outcomes.